Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 13/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 3/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23297169 | 1.00 | NPBWR1 (0.48) | NPBWR1MCHR1RAF1CCNB2CCNE2 | |
| SCHEMBL24640483 | 0.91 | NPBWR1 (0.49) | NPBWR1MCHR1RAF1CCNB2CCNE2 | |
| SCHEMBL23297046 | 0.87 | NPBWR1 (0.44) | NPBWR1MCHR1RAF1CCNB2CCNE2 | |
| SCHEMBL23297051 | 0.87 | NPBWR1 (0.44) | NPBWR1MCHR1RAF1CCNB2CCNE2 | |
| SCHEMBL24687640 | 0.87 | NPBWR1 (0.51) | NPBWR1MCHR1RAF1CCNB2CCNE2 | |
| SCHEMBL24640479 | 0.87 | NPBWR1 (0.51) | NPBWR1MCHR1RAF1CCNB2CCNE2 | |
| SCHEMBL21521227 | 0.87 | NPBWR1 (0.51) | NPBWR1MCHR1RAF1CCNB2CCNE2 | |
| SCHEMBL21521225 | 0.87 | NPBWR1 (0.51) | NPBWR1MCHR1RAF1CCNB2CCNE2 | |
| SCHEMBL24640391 | 0.87 | NPBWR1 (0.44) | NPBWR1MCHR1RAF1CCNB2CCNE2 | |
| SCHEMBL24639951 | 0.87 | NPBWR1 (0.44) | NPBWR1MCHR1RAF1CCNB2CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20240034728-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2024-02-01 | — | — | US | disclosed |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | RIBON THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | RIBON THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2022184103-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 武汉誉祥医药科技有限公司 | 2022-09-09 | — | — | WO | disclosed |
| EP-4051384-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114761086-A | Pyridazinones as PARP7 inhibitors | 里邦医疗公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20210130342-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-05-06 | — | — | US | disclosed |
| US-20210130342-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-05-06 | — | — | US | disclosed |
| WO-2021087025-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021087025-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130342-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | NPBWR1 4538/4885MCHR1 4728/4885RAF1 1368/4885 |
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | PARP3, PARP2, PARP1 | NPBWR1 2135/4885MCHR1 4315/4885RAF1 134/4885 |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | PARP2, PARP1, PARP4 | NPBWR1 4624/4885MCHR1 4691/4885RAF1 1253/4885 |
| US-20240034728-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | NPBWR1 4538/4885MCHR1 4728/4885RAF1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.